According with these data, several studies have shown that among patients with HNSCC and OPSCC managed with different treatment modalities, those with p16-positive tumors have a better prognosis in terms of response, recurrence and survival than patients with p16-negative tumors [14,22-24]. Here, CDKN2A is linked to head and neck squamous cell carcinoma.